Logo
x

Search

Subscribe Now

ALS

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

  • November 3, 2021
Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS

Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS

  • July 9, 2021
Abbisko Signs an Exclusive License Agreement with Sperogenix to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China

Abbisko Signs an Exclusive License Agreement with Sperogenix to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Gr...

  • July 6, 2021
BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia

  • October 29, 2020
Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS)

Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS)

  • November 13, 2019
Columbia's Zuckerman Institute Develops an AI-based Brain-Computer Interface (BCI) for People with Aphasia & Amyotrophic Lateral Sclerosis (ALS)

Columbia's Zuckerman Institute Develops an AI-based Brain-Computer Interface (BCI) for People with Aphasia & Amyotrophic Later...

  • January 31, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.